Anixa Biosciences director exercises 6,000 options

Arnold M. Baskies, a director of Anixa Biosciences Inc, exercised employee stock options covering 6,000 shares of common stock on July 27, 2026 at an exercise price of $3.1300 per share.

Rhea-AI Filing Summary

Arnold M. Baskies, a director of Anixa Biosciences Inc, exercised employee stock options covering 6,000 shares of common stock on July 27, 2026 at an exercise price of $3.1300 per share. These options were granted on August 23, 2013 and were approaching expiration on August 23, 2026.

To cover the option exercise cost, 5,428 shares of common stock were withheld by Anixa Biosciences Inc at $3.4600 per share. Following this exercise, the related stock option position reported for this grant was reduced to 0 derivative securities.

Insider Trade Summary

6,000 shares exercised/converted

Exercise 3 txns

Insider Baskies Arnold M

Role Director

Type	Security	Shares	Price	Value
Exercise	Employee Stock Option (Right to Buy) F2	6,000	$0.00	$0.00
Exercise	Common Stock	6,000	$3.13	$19K
Exercise Price Payment	Common Stock F1	5,428	$3.46	$19K

Holdings After Transaction: Employee Stock Option (Right to Buy) — 0 contracts (Direct); Common Stock — 135,572 shares (Direct)

Footnotes (2)

1. F1. The reporting person exercised the stock options at this time due to their expiration on August 23, 2026. The disposal of shares reported herein represents shares withheld by Anixa Biosciences, Inc. (the "registrant") to cover the exercise price of the stock options.
2. F2. Right-To-Buy, pursuant to a stock option grant dated August 23, 2013.

Key Figures

Options Exercised: 6000.0000 shares Option Exercise Price: $3.1300 per share Shares Withheld: 5428.0000 shares +3 more

6 metrics

Options Exercised 6000.0000 shares Employee stock options exercised for common stock on 2026-07-27

Option Exercise Price $3.1300 per share Exercise price of employee stock options granted August 23, 2013

Shares Withheld 5428.0000 shares Common shares withheld to cover exercise price at $3.4600 per share

Withholding Share Price $3.4600 per share Price used for shares withheld to pay the option exercise cost

Options Remaining from Grant 0.0000 derivative securities Total derivative securities following transaction for this option grant

Option Expiration Date 2026-08-23 Expiration date of stock option grant exercised by the director

Key Terms

Employee Stock Option (Right to Buy), exercise price, stock option grant, withheld

4 terms

Employee Stock Option (Right to Buy) financial

"security_title: Employee Stock Option (Right to Buy)"

exercise price financial

"Payment of exercise price by delivering or withholding securities"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

stock option grant financial

"pursuant to a stock option grant dated August 23, 2013"

withheld financial

"represents shares withheld by Anixa Biosciences, Inc. to cover the exercise price"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What transaction did Arnold M. Baskies report for Anixa Biosciences (ANIX)?

Arnold M. Baskies reported exercising 6,000 employee stock options for Anixa Biosciences common stock. The exercise occurred on July 27, 2026, using options granted in 2013 that were nearing their August 23, 2026 expiration date.

At what price did the ANIX director exercise his stock options?

The ANIX director exercised his options at an exercise price of $3.1300 per share. These options related to 6,000 shares of common stock and were originally granted on August 23, 2013 under a Right-To-Buy stock option grant.

How many ANIX shares were withheld to cover the option exercise cost?

Anixa Biosciences withheld 5,428 shares of common stock to cover the exercise cost. The withheld shares were valued at $3.4600 per share, as disclosed in connection with the payment of the exercise price for the option exercise.

What happened to the option position after the ANIX option exercise?

After the transaction, the director’s reported derivative position from this grant was reduced to 0 stock options. The footnotes explain the options were exercised at this time because they were approaching their August 23, 2026 expiration date.

Were the ANIX transactions part of a Rule 10b5-1 trading plan?

The disclosure indicates the Rule 10b5-1 checkbox was not affirmatively marked for these transactions. No footnote states that the option exercise or share withholding occurred under a pre-arranged Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/29/2026 - 09:15 AM Accepted by SEC EDGAR 07/29/2026 - 09:14 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Baskies Arnold M

(Last) (First) (Middle)

C/O ANIXA BIOSCIENCES, INC.

3150 ALMADEN EXPRESSWAY, SUITE 250

(Street)

SAN JOSE, CALIFORNIA 95118

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Anixa Biosciences Inc [ ANIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/27/2026		M		6,000	A	$3.13	141,000	D
Common Stock	07/27/2026		F(1)		5,428	D	$3.46	135,572	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)(2)	$3.13	07/27/2026		M			6,000	08/23/2016	08/23/2026	Common Stock	6,000	$0	0	D

Explanation of Responses:

1. The reporting person exercised the stock options at this time due to their expiration on August 23, 2026. The disposal of shares reported herein represents shares withheld by Anixa Biosciences, Inc. (the "registrant") to cover the exercise price of the stock options.

2. Right-To-Buy, pursuant to a stock option grant dated August 23, 2013.

	/s/ Arnold M. Baskies	07/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)